![Richard Seabrook](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard Seabrook
Corporate Officer/Principal bei Wellcome Trust Technology Transfer
Aktive Positionen von Richard Seabrook
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Wellcome Trust Technology Transfer
![]() Wellcome Trust Technology Transfer Investment ManagersFinance Wellcome Trust Technology Transfer (Wellcome Trust Technology Transfer) is a venture capital subsidiary of The Wellcome Trust Ltd. founded in 1992 by Graham Eric Fagg. The firm is headquartered in London. | Corporate Officer/Principal | 01.01.1998 | - |
Karriereverlauf von Richard Seabrook
Ehemalige bekannte Positionen von Richard Seabrook
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Quadrant Healthcare Plc
![]() Quadrant Healthcare Plc Pharmaceuticals: MajorHealth Technology Part of Perrigo Co. Plc, Quadrant Healthcare Plc is a British company that researches, develops, and formulates drugs. The company is based in Cambridge, UK. Quadrant Healthcare was acquired by Elan Europe Ltd. on January 11, 2001 for $69.60 million. | Corporate Officer/Principal | - | - |
Acesion Pharma ApS
![]() Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | - | - |
ProXara Biotechnology Ltd.
![]() ProXara Biotechnology Ltd. Pharmaceuticals: MajorHealth Technology ProXara Biotechnology Limited is a recently-formed biotechnology company whose mission is to be a world leader in the development of novel therapeutically-relevant cell-based and in-vitro high throughput screens for drug discovery in the oncology field. The Company was founded by Professor Jeremy Tavaré in the Department of Biochemistry at the University of Bristol and was incorporated in March 2001. The company is supported by an experienced and entrepreneurial management team. ProXara has received funding from the Sulis Seedcorn Fund Partnership Limited, Catalyst BioMedica, The Wellcome Trust and private sources. Its premises are currently in the School of Medical Sciences in the University of Bristol. ProXara has established a portfolio of novel cell-based and in-vitro assays against important intra-cellular targets in cancer (primarily breast and prostate) for screening against both internal and customer compound collections. Breast and prostate cancers are the most prevalent malignancies in women and men respectively, and the second highest cause of cancer deaths. The company's technologies will allow the discovery of drugs with a completely novel mode of action against relevant and validated targets. ProXara is currently undertaking optimization of a series of proprietary drug-like molecules which could provide a novel route for the treatment of cancer. | Direktor/Vorstandsmitglied | - | - |
Statistik
International
Vereinigtes Königreich | 4 |
Dänemark | 2 |
Operativ
Director/Board Member | 2 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 4 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
ProXara Biotechnology Ltd.
![]() ProXara Biotechnology Ltd. Pharmaceuticals: MajorHealth Technology ProXara Biotechnology Limited is a recently-formed biotechnology company whose mission is to be a world leader in the development of novel therapeutically-relevant cell-based and in-vitro high throughput screens for drug discovery in the oncology field. The Company was founded by Professor Jeremy Tavaré in the Department of Biochemistry at the University of Bristol and was incorporated in March 2001. The company is supported by an experienced and entrepreneurial management team. ProXara has received funding from the Sulis Seedcorn Fund Partnership Limited, Catalyst BioMedica, The Wellcome Trust and private sources. Its premises are currently in the School of Medical Sciences in the University of Bristol. ProXara has established a portfolio of novel cell-based and in-vitro assays against important intra-cellular targets in cancer (primarily breast and prostate) for screening against both internal and customer compound collections. Breast and prostate cancers are the most prevalent malignancies in women and men respectively, and the second highest cause of cancer deaths. The company's technologies will allow the discovery of drugs with a completely novel mode of action against relevant and validated targets. ProXara is currently undertaking optimization of a series of proprietary drug-like molecules which could provide a novel route for the treatment of cancer. | Health Technology |
Wellcome Trust Technology Transfer
![]() Wellcome Trust Technology Transfer Investment ManagersFinance Wellcome Trust Technology Transfer (Wellcome Trust Technology Transfer) is a venture capital subsidiary of The Wellcome Trust Ltd. founded in 1992 by Graham Eric Fagg. The firm is headquartered in London. | Finance |
Quadrant Healthcare Plc
![]() Quadrant Healthcare Plc Pharmaceuticals: MajorHealth Technology Part of Perrigo Co. Plc, Quadrant Healthcare Plc is a British company that researches, develops, and formulates drugs. The company is based in Cambridge, UK. Quadrant Healthcare was acquired by Elan Europe Ltd. on January 11, 2001 for $69.60 million. | Health Technology |
Acesion Pharma ApS
![]() Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Börse
- Insiders
- Richard Seabrook
- Erfahrung